in ,

WHO advises against the use of Remdesivir to treat COVID-19 patients due to lack of results

The WHO advises against the use of remdesivir for patients with COVID-19.  EFE / EPA / SASCHA STEINBACH / Archive The WHO advises against the use of remdesivir for patients with COVID-19. . / EPA / SASCHA STEINBACH / Archive

An advisory body to the World Health Organization (WHO) announced this Thursday that it does not recommend the use of the antiviral drug Remdesivir to treat hospitalized COVID-19 patients.as there is insufficient evidence that it improves your condition or reduces the need for artificial ventilation assistance.

The WHO recommendation is based on new evidence comparing the effects of various drugs in treating coronavirus and includes data from four randomized international trials involving more than 7,000 hospitalized patients with COVID-19.

These results have been published by a panel of international experts from the WHO Guidelines Development Group in the medical journal BMJ – published by the British Medical Association – and They are part of the so-called “living guides” to deal with COVID-19 with the intention of helping health personnel to make better decisions in their management.

After reviewing the evidence, the experts conclude that remdesivir given intravenously “does not have a significant effect on mortality or other important patient outcomes, such as the need for mechanical ventilation or time to clinical improvement.”

In this sense, recall that the certainty of the antiviral results is low and add that there is no proof that Remdesivir has any benefit.

A Gilead Sciences COVID-19 antiviral remdesivir ampoule is displayed during a press conference at Eppendorf University Hospital (UKE) in Hamburg, Germany.  April 8, 2020. Ulrich Perrey / Pool via REUTERS A Gilead Sciences COVID-19 antiviral remdesivir ampoule is displayed during a press conference at Eppendorf University Hospital (UKE) in Hamburg, Germany. April 8, 2020. Ulrich Perrey / Pool via REUTERS

Still, the expert group has encouraged the enrollment of more patients in Remdesivir trials for more substantial evidence, especially in relation to specific groups of patients, impact.

Likewise, the WHO has considered that “the complete history of Remdesivir will not be understood until its manufacturer, Gilead, publishes the full reports of the clinical studies. “

Remdesivir has received worldwide attention in the treatment of severe cases of coronavirus and is being used increasingly in hospitalized patients, especially in the United States, where it was even administered to the president, Donald Trump.

For its part, Gilead Sciences, the manufacturer of the antiviral, has claimed to be “disappointed that the WHO guidelines appear to ignore the results”, a recommendation from the world body based on a report with data that has not been made publicly available or peer-reviewed.

“The recommendations of credible institutions for the use of Remdesivir as standard treatment are based on strong evidence from multiple randomized and controlled studies published in peer-reviewed journals that demonstrate the clinical benefits of Remdesivir,” the company said in a statement.

With information from Europa Press

MORE ON THIS TOPIC:

The controversy over Remdesivir, the only treatment approved so far against COVID-19

The United States Fully Authorized Remdesivir as a Treatment for COVID-19

A new study confirmed the effectiveness of Remdesivir in treatments against the coronavirus